Accuray Stock Forecast, Price & News

+0.22 (+5.68 %)
(As of 08/4/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume628,246 shs
Average Volume775,248 shs
Market Capitalization$381.44 million
P/E Ratio102.28
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

Accuray logo

About Accuray

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.


Accuray (ARAY) to Release Quarterly Earnings on Wednesday
Accuray (ARAY) to Release Quarterly Earnings on Wednesday
August 4, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.29 out of 5 stars

Medical Sector

255th out of 1,311 stocks

Surgical & Medical Instruments Industry

28th out of 121 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Accuray (NASDAQ:ARAY) Frequently Asked Questions

Is Accuray a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Accuray stock.
View analyst ratings for Accuray
or view top-rated stocks.

What stocks does MarketBeat like better than Accuray?

Wall Street analysts have given Accuray a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Accuray wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Accuray's next earnings date?

Accuray is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Accuray

How can I listen to Accuray's earnings call?

Accuray will be holding an earnings conference call on Wednesday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "10158497".

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) posted its earnings results on Tuesday, January, 26th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.01) by $0.06. The medical equipment provider had revenue of $97.46 million for the quarter, compared to the consensus estimate of $92.85 million. Accuray had a net margin of 1.04% and a trailing twelve-month return on equity of 5.51%. During the same quarter last year, the business earned $0.12 earnings per share.
View Accuray's earnings history

How has Accuray's stock price been impacted by Coronavirus?

Accuray's stock was trading at $2.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARAY shares have increased by 80.2% and is now trading at $4.09.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ARAY?

2 brokers have issued twelve-month price targets for Accuray's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Accuray's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 46.7% from the stock's current price.
View analysts' price targets for Accuray
or view top-rated stocks among Wall Street analysts.

Who are Accuray's key executives?

Accuray's management team includes the following people:
  • Mr. Joshua H. Levine, Pres, CEO & Director (Age 63, Pay $739.26k)
  • Mr. Shigeyuki Hamamatsu, Sr. VP & CFO (Age 48, Pay $420.51k)
  • Mr. Patrick R. Spine, Sr. VP & Chief Admin. Officer (Age 50, Pay $395.87k)
  • Mr. Jesse Chew, Sr. VP, Gen. Counsel & Corp. Sec. (Age 40, Pay $396.02k)
  • Ms. Suzanne Winter, Chief Commercial Officer and Sr. VP of R&D (Age 58, Pay $657.6k)
  • Mr. Michael Hoge, Sr. VP of Global Operations
  • Dr. Jean-Philippe Pignol, Sr. VP, Chief Medical & Technology Officer
  • Ken Mobeck, VP of Fin. & Investor Relations
  • Beth Kaplan, PR Director
  • Mr. Scott Chapman, Sr. VP of Global Service

What is Joshua Levine's approval rating as Accuray's CEO?

78 employees have rated Accuray CEO Joshua Levine on Joshua Levine has an approval rating of 45% among Accuray's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Accuray's key competitors?

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Who are Accuray's major shareholders?

Accuray's stock is owned by many different institutional and retail investors. Top institutional shareholders include Kovack Advisors Inc. (0.86%), Russell Investments Group Ltd. (0.75%), Rice Hall James & Associates LLC (0.51%), Cowen Prime Advisors LLC (0.18%), Victory Capital Management Inc. (0.05%) and Hussman Strategic Advisors Inc. (0.03%). Company insiders that own Accuray stock include Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Shigeyuki Hamamatsu and Suzanne C Winter.
View institutional ownership trends for Accuray

Which major investors are selling Accuray stock?

ARAY stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, and Hussman Strategic Advisors Inc.. Company insiders that have sold Accuray company stock in the last year include Jesse Chew, Joshua Levine, Shigeyuki Hamamatsu, and Suzanne C Winter.
View insider buying and selling activity for Accuray
or view top insider-selling stocks.

Which major investors are buying Accuray stock?

ARAY stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Cowen Prime Advisors LLC, Kovack Advisors Inc., Victory Capital Management Inc., and Clear Creek Financial Management LLC.
View insider buying and selling activity for Accuray
or or view top insider-buying stocks.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $4.09.

How much money does Accuray make?

Accuray has a market capitalization of $381.44 million and generates $382.93 million in revenue each year. The medical equipment provider earns $3.83 million in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does Accuray have?

Accuray employs 932 workers across the globe.

What is Accuray's official website?

The official website for Accuray is

Where are Accuray's headquarters?

Accuray is headquartered at 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]

This page was last updated on 8/5/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.